CD33 and colorectal carcinoma: A recent study found that the anti-CD33 immunotoxin (gemtuzumab ozogamicin) could decrease MDSCs, opening the door for using it to reactivate T cells and chimeric-antigen receptor T cell (CAR-T) against various malignancies such as CRC, breast cancer, and melanoma [85].